

Commissioner of Patents and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement accompanies the new patent application submitted herewith of the following Inventor(s):

Andrew S. Katocs, Jr., Elwood Largis,
Sotirios K. Karathanasis;

For: USE OF RETINOIDS FOR THE TREATMENT AND PREVENTION OF
CORONARY ARTERY DISEASE

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date March 31, 1992 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number GB652950067US addressed to the: Commissioner of Patents and Trademarks, Washington, D.C 20231.

Benedict A. Jablonski

(name of person mailing paper)

Benedict A. Jablonski

(Signature of person mailing paper)

2. [] Previously Cited Information

Prior application is Serial No. _____,
filed on _____ of _____
(date) (inventors)
_____, _____,
for _____.

A legible copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed, except that no copy of a pending U. S. application is enclosed.

Documents cited above which are not in the English language

- a. [] have been explained in the specification.
- b. [] have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

INFORMATION DISCLOSURE (NewApp)
[REV. 4MAR92]

5. Form PTO-1449 is enclosed in duplicate.



Kenneth J. Dow

Reg. No. 32,890

Tel. No. (203) 321-2659

American Cyanamid Company
1937 West Main Street
P.O. Box 60
Stamford, CT 06904-0060